The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

Table 3

Some antibodies against pathogenic bacteria in clinical research.


Antibody	Evaluated condition	Target	Clinical trial phase	Method of generation	Reference

MEDI4893	S. aureus pneumonia	Alpha toxin	Phase IIb	Hybridoma technology	[178–180]
ASN100	Staphylococcal infections	Alpha toxin, leukocidins	Phase II	Yeast surface display	[181, 182]
AR-301	S. aureus lung infections	Human leukocyte antigen	Phase III	Screening human B-cells of convalescent pneumonia patients	[183]
514G3	S. Aureus bacteremia	SpA	Phase II	B-cell isolation	[184, 185]
AR-101	P. aeruginosa infections	LPS	Phase IIa	Screening of the B-cell repertoire	[186]
MEDI3902	P. aeruginosa pneumonia	PcrV and Psl	Phase II	Phage display	[187–189]
KB001-A	P. aeruginosa infections	PcrV	Phase II	Hybridoma technology	[190, 191]
Raxibacumab	Anthrax	Protective antigen	FDA approved	Phage display	[192]
Anthim	Anthrax	Protective antigen	Phase I	Mouse hybridoma	[193]
Bezlotuxumab	C. difficile infections	Toxin B	FDA approved	Mouse immunization	[194, 195]
Shigamabs	Shiga toxin-producing infections	Shiga toxin 1 and 2	Phase II	Mouse hybridoma	[196]